{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:28:34Z","timestamp":1768408114601,"version":"3.49.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15366-4","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T10:43:47Z","timestamp":1764413027000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative survival outcomes between therapy-related and de novo acute lymphoblastic leukemia in adults: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Rowan","family":"Mesilhy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Naseem","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asma","family":"Syed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razan","family":"Hourani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honar","family":"Cherif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmin","family":"Elsalkawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafsa","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrahman","family":"Al-Mashdali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deena","family":"Mudwai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suhail A.","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shehab F.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"issue":"24","key":"15366_CR1","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1182\/bloodadvances.2019000925","volume":"3","author":"C Saygin","year":"2019","unstructured":"Saygin C, Kishtagari A, Cassaday RD, Reizine N, Yurkiewicz I, Liedtke M, et al. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Adv. 2019;3(24):4228\u201337. https:\/\/doi.org\/10.1182\/bloodadvances.2019000925.","journal-title":"Blood Adv"},{"issue":"10","key":"15366_CR2","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3324\/haematol.2018.193599","volume":"103","author":"I Aldoss","year":"2018","unstructured":"Aldoss I, Stiller T, Tsai NC, Song JY, Cao T, Bandara NA, et al. Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de Novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients. Haematologica. 2018;103(10):1662\u20138. https:\/\/doi.org\/10.3324\/haematol.2018.193599.","journal-title":"Haematologica"},{"issue":"4","key":"15366_CR3","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1046\/j.1365-2141.1999.01636.x","volume":"106","author":"L Pagano","year":"1999","unstructured":"Pagano L, Pulsoni A, Tosti ME, Annino L, Mele A, Camera A, et al. Acute lymphoblastic leukaemia occurring as second malignancy: report of the GIMEMA archive of adult acute leukaemia. Br J Haematol. 1999;106(4):1037\u201340. https:\/\/doi.org\/10.1046\/j.1365-2141.1999.01636.x.","journal-title":"Br J Haematol"},{"issue":"6","key":"15366_CR4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/sj.leu.2402918","volume":"17","author":"S Ishizawa","year":"2003","unstructured":"Ishizawa S, Slovak ML, Popplewell L, Bedell V, Wrede JE, Carter NH, et al. High frequency of pro-B acute lymphoblastic leukemia in adults with secondary leukemia with 11q23 abnormalities. Leukemia. 2003;17(6):1091\u20135. https:\/\/doi.org\/10.1038\/sj.leu.2402918.","journal-title":"Leukemia"},{"issue":"2","key":"15366_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/cam4.1266","volume":"7","author":"A Swaika","year":"2017","unstructured":"Swaika A, Frank RD, Yang D, Finn LE, Jiang L, Advani P, et al. Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes. Cancer Med. 2017;7(2):499\u2013507. https:\/\/doi.org\/10.1002\/cam4.1266.","journal-title":"Cancer Med"},{"issue":"12","key":"15366_CR6","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.leukres.2015.09.011","volume":"39","author":"S Giri","year":"2015","unstructured":"Giri S, Chi M, Johnson B, McCormick D, Jamy O, Bhatt VR, et al. Secondary acute lymphoblastic leukemia is an independent predictor of poor prognosis. Leuk Res. 2015;39(12):1342\u20136. https:\/\/doi.org\/10.1016\/j.leukres.2015.09.011.","journal-title":"Leuk Res"},{"issue":"4","key":"15366_CR7","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/bjh.17906","volume":"196","author":"Z Rahman","year":"2021","unstructured":"Rahman Z, Parrondo R, Heckman M, Wieczorek M, Miller K, Alkhateeb H, et al. Comparative study of therapy-related and de Novo adult b\u2010cell acute lymphoblastic leukaemia. Br J Haematol. 2021;196(4):963\u20138. https:\/\/doi.org\/10.1111\/bjh.17906.","journal-title":"Br J Haematol"},{"issue":"3","key":"15366_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1590\/S1677-5538.IBJU.2017.03.03","volume":"43","author":"WM Bernardo","year":"2017","unstructured":"Bernardo WM, Int Braz. J Urol. 2017;43(3):383\u20134. https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2017.03.03.","journal-title":"J Urol"},{"issue":"2","key":"15366_CR9","doi-asserted-by":"publisher","first-page":"e1230","DOI":"10.1002\/cl2.1230","volume":"18","author":"NR Haddaway","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis. Campbell Syst Rev. 2022;18(2):e1230. https:\/\/doi.org\/10.1002\/cl2.1230.","journal-title":"Campbell Syst Rev"},{"issue":"2","key":"15366_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/jebm.12618","volume":"17","author":"AI Ahmed","year":"2024","unstructured":"Ahmed AI, et al. Master scale for methodological quality assessment: reliability assessment and update. J Evid Based Med. 2024;17(2):263\u20136. https:\/\/doi.org\/10.1111\/jebm.12618.","journal-title":"J Evid Based Med"},{"issue":"8","key":"15366_CR11","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.jval.2021.02.011","volume":"24","author":"JC Stone","year":"2021","unstructured":"Stone JC, Gurunathan U, Aromataris E, Glass K, Tugwell P, Munn Z, Doi SAR. Bias assessment in outcomes research: the role of relative versus absolute approaches. Value Health. 2021;24(8):1145\u20139. https:\/\/doi.org\/10.1016\/j.jval.2021.02.011.","journal-title":"Value Health"},{"key":"15366_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jclinepi.2019.09.010","volume":"117","author":"JC Stone","year":"2020","unstructured":"Stone JC, Glass K, Munn Z, Tugwell P, Doi SAR. Comparison of bias adjustment methods in meta-analysis suggests that quality effects modeling May have less limitations than other approaches. J Clin Epidemiol. 2020;117:36\u201345. https:\/\/doi.org\/10.1016\/j.jclinepi.2019.09.010.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"15366_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/XEB.0000000000000207","volume":"18","author":"SAR Doi","year":"2020","unstructured":"Doi SAR, Furuya-Kanamori L. Selecting the best meta-analytic estimator for evidence-based practice: a simulation study. Int J Evid Based Healthc. 2020;18(1):86\u201394. https:\/\/doi.org\/10.1097\/XEB.0000000000000207.","journal-title":"Int J Evid Based Healthc"},{"issue":"4","key":"15366_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/XEB.0000000000000125","volume":"15","author":"SAR Doi","year":"2017","unstructured":"Doi SAR, Furuya-Kanamori L, Thalib L, Barendregt JJ. Meta-analysis in evidence-based healthcare: a paradigm shift away from random effects is overdue. Int J Evid Based Healthc. 2017;15(4):152\u201360. https:\/\/doi.org\/10.1097\/XEB.0000000000000125.","journal-title":"Int J Evid Based Healthc"},{"issue":"3","key":"15366_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/XEB.0000000000000058","volume":"13","author":"SA Doi","year":"2015","unstructured":"Doi SA. Meta-analysis and the problem of inconsistent effects. Int J Evid Based Healthc. 2015;13(3):115\u20136.","journal-title":"Int J Evid Based Healthc"},{"issue":"28","key":"15366_CR16","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1002\/sim.4350","volume":"30","author":"H Noma","year":"2011","unstructured":"Noma H. Confidence intervals for a random-effects meta-analysis based on Bartlett-type corrections. Stat Med. 2011;30(28):3304\u201312. https:\/\/doi.org\/10.1002\/sim.4350.","journal-title":"Stat Med"},{"issue":"1","key":"15366_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1536867X0800800102","volume":"8","author":"RJ Harris","year":"2008","unstructured":"Harris RJ, Deeks JJ, Altman DG, Bradburn MJ, Harbord RM, Sterne JA. Metan: fixed- and random-effects meta-analysis. Stata J. 2008;8(1):3\u201328.","journal-title":"Stata J"},{"issue":"7414","key":"15366_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"4","key":"15366_CR19","first-page":"195","volume":"16","author":"L Furuya-Kanamori","year":"2018","unstructured":"Furuya-Kanamori L, Barendregt JJ, Doi SA. A new improved graphical and quantitative method for detecting bias in meta-analysis. JBI Evid Implement. 2018;16(4):195\u2013203.","journal-title":"JBI Evid Implement"},{"key":"15366_CR20","doi-asserted-by":"publisher","unstructured":"Bloomfield CD, Archer KJ, Mr\u00f3zek K, Lillington DM, Kaneko Y, Head DR, et al. 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international Workshop\u2020. Genes Chromosomes Cancer. 2002;33(4):362\u201378. https:\/\/doi.org\/10.1002\/gcc.10046.","DOI":"10.1002\/gcc.10046"},{"issue":"5","key":"15366_CR21","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/s1568-7864(03)00020-x","volume":"2","author":"I Casorelli","year":"2003","unstructured":"Casorelli I. Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome. DNA Repair. 2003;2(5):547\u201359. https:\/\/doi.org\/10.1016\/s1568-7864(03)00020-x.","journal-title":"DNA Repair"},{"issue":"3","key":"15366_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5045\/kjh.2010.45.3.177","volume":"45","author":"H Shim","year":"2010","unstructured":"Shim H, Chi HS, Jang S, Seo EJ, Park CJ, Lee JH, et al. Therapy-related acute leukemia in breast cancer patients: twelve cases treated with a topoisomerase inhibitor. Korean J Hematol. 2010;45(3):177. https:\/\/doi.org\/10.5045\/kjh.2010.45.3.177.","journal-title":"Korean J Hematol"},{"issue":"16","key":"15366_CR23","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/cncr.26735","volume":"118","author":"A Abdulwahab","year":"2011","unstructured":"Abdulwahab A, Sykes J, Kamel-Reid S, Chang H, Brandwein JM. Therapy\u2010related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis. Cancer. 2011;118(16):3962\u20137. https:\/\/doi.org\/10.1002\/cncr.26735.","journal-title":"Cancer"},{"key":"15366_CR24","doi-asserted-by":"publisher","unstructured":"Tang G, Zuo Z, Thomas DA, Lin P, Liu D, Hu Y et al. Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related? Haematologica. 2011;97(6):919\u201325. https:\/\/doi.org\/10.3324\/haematol.2011.057752","DOI":"10.3324\/haematol.2011.057752"},{"issue":"1","key":"15366_CR25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjh.13386","volume":"170","author":"C Ganzel","year":"2015","unstructured":"Ganzel C, Devlin S, Douer D, Rowe JM, Stein EM, Tallman MS. Secondary acute lymphoblastic leukaemia is constitutional and probably not related to prior therapy. Br J Haematol. 2015;170(1):50\u20135. https:\/\/doi.org\/10.1111\/bjh.13386.","journal-title":"Br J Haematol"},{"issue":"2","key":"15366_CR26","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/cncr.29615","volume":"122","author":"JE Churpek","year":"2015","unstructured":"Churpek JE, Marquez R, Neistadt B, Claussen K, Lee MK, Churpek MM, et al. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer. 2015;122(2):304\u201311. https:\/\/doi.org\/10.1002\/cncr.29615.","journal-title":"Cancer"},{"key":"15366_CR27","doi-asserted-by":"publisher","unstructured":"Lu QS, Xu N, Zhou X, Cai GX, Li L, Li YL et al. Clinical characteristics and prognosis of 35 patients with therapy-related hematological neoplasms. Zhonghua Xue Ye Xue Za Zhi. 2016;37(3):221-6. Chinese. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2016.03.009","DOI":"10.3760\/cma.j.issn.0253-2727.2016.03.009"},{"key":"15366_CR28","doi-asserted-by":"publisher","unstructured":"Kelleher N, Gallardo D, Gonz\u00e1lez-Campos J, Hern\u00e1ndez-Rivas JM, Montesinos P, Sarr\u00e1 J et al. Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy. Leuk Lymphoma\/Leukemia Lymphoma 2015Apr11;57(1):86\u201391 https:\/\/doi.org\/10.3109\/10428194.2015.1040013","DOI":"10.3109\/10428194.2015.1040013"},{"issue":"42","key":"15366_CR29","doi-asserted-by":"publisher","first-page":"68526","DOI":"10.18632\/oncotarget.12031","volume":"7","author":"E Fabiani","year":"2017","unstructured":"Fabiani E, Diverio D, Pisani F, Baldacci E, Elia L, Fortunato A, et al. Therapy-related acute lymphoblastic leukemia: a distinctive subtype of acute lymphoblastic leukemia? Oncotarget. 2017;7(42):68526\u201336. https:\/\/doi.org\/10.18632\/oncotarget.12031.","journal-title":"Oncotarget"},{"key":"15366_CR30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.leukres.2018.07.024","volume":"72","author":"F Ferraro","year":"2018","unstructured":"Ferraro F, Gao F, Stockerl-Goldstein K, Westervelt P, DiPersio JF, Ghobadi A. Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington university and meta-analysis of published data. Leuk Res. 2018;72:86\u201391. https:\/\/doi.org\/10.1016\/j.leukres.2018.07.024.","journal-title":"Leuk Res"},{"issue":"1","key":"15366_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ejh.13403","volume":"105","author":"RV Nampoothiri","year":"2020","unstructured":"Nampoothiri RV, Law AD, Lam W, Chen C, Al-Shaibani Z, Loach D, et al. Outcomes of therapy\u2010related acute lymphoblastic leukemia in adults after allogeneic stem cell transplantation. Eur J Haematol. 2020;105(1):24\u20139. https:\/\/doi.org\/10.1111\/ejh.13403.","journal-title":"Eur J Haematol"},{"issue":"12","key":"15366_CR32","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.7150\/jca.76719","volume":"13","author":"HW Kook","year":"2022","unstructured":"Kook HW, Kim JJ, Park MR, Jang JE, Min YH, Lee ST, et al. Therapy-related acute lymphoblastic leukaemia has a unique genetic profile compared to de Novo acute lymphoblastic leukaemia. J Cancer. 2022;13(12):3326\u201332. https:\/\/doi.org\/10.7150\/jca.76719.","journal-title":"J Cancer"},{"issue":"2","key":"15366_CR33","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/ijc.33216","volume":"148","author":"MJ Jabagi","year":"2020","unstructured":"Jabagi MJ, Vey N, Goncalves A, Tri TL, Zureik M, Dray-spira R. Risk of secondary hematologic malignancies associated with breast cancer chemotherapy and G\u2010CSF support: A nationwide population\u2010based cohort. Int J Cancer. 2020;148(2):375\u201384. https:\/\/doi.org\/10.1002\/ijc.33216.","journal-title":"Int J Cancer"},{"issue":"5","key":"15366_CR34","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/ejh.13750","volume":"108","author":"RV Nampoothiri","year":"2022","unstructured":"Nampoothiri RV, Pasic I, Law AD, Lam W, Chen C, Michelis FV, et al. Allogeneic hematopoietic stem cell transplantation in patients with therapy-related hematologic malignancies developing after multiple myeloma. Eur J Haematol. 2022;108(5):430\u20136. https:\/\/doi.org\/10.1111\/ejh.13750.","journal-title":"Eur J Haematol"},{"issue":"13","key":"15366_CR35","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1182\/bloodadvances.2022009212","volume":"7","author":"MB Geyer","year":"2023","unstructured":"Geyer MB, Shaffer BC, Bhatnagar B, Mims AS, Klein V, Dilip D, et al. Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to Lenalidomide withdrawal. Blood Adv. 2023;7(13):3087\u201398. https:\/\/doi.org\/10.1182\/bloodadvances.2022009212.","journal-title":"Blood Adv"},{"key":"15366_CR36","doi-asserted-by":"publisher","unstructured":"Elghawy O, Deshpande S, Sussman J, Garfall A, Cohen A, Kapur S et al. Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma. Bone Marrow Transplantation 2024 Oct 30. https:\/\/doi.org\/10.1038\/s41409-024-02455-4","DOI":"10.1038\/s41409-024-02455-4"},{"issue":"3","key":"15366_CR37","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41409-023-02192-0","volume":"59","author":"A Sadowska-Klasa","year":"2024","unstructured":"Sadowska-Klasa A, Zaucha JM, Labopin M, Bourhis JH, Blaise D, Yakoub-Agha I, et al. Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL\u2014a report from the EBMT registry. Bone Marrow Transplant. 2024;59(3):387\u201394. https:\/\/doi.org\/10.1038\/s41409-023-02192-0.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"15366_CR38","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1080\/10428194.2024.2315171","volume":"65","author":"KD Hofer","year":"2024","unstructured":"Hofer KD, B\u00fchler MM, Roncador M, Rechsteiner M, Maggio EM, Tchinda J, et al. Mutational patterns in therapy-related acute lymphoblastic leukemia subgroups: one step closer to unveiling the genetic odyssey. Leuk Lymphoma\/Leukemia Lymphoma. 2024;65(6):808\u201315. https:\/\/doi.org\/10.1080\/10428194.2024.2315171.","journal-title":"Leuk Lymphoma\/Leukemia Lymphoma"},{"issue":"1","key":"15366_CR39","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/bjh.19432","volume":"205","author":"H Pourhassan","year":"2024","unstructured":"Pourhassan H, Zhang J, Tinajero J, Pullarkat V, Agrawal V, Koller P, et al. Therapy-related acute lymphoblastic leukaemia in women with antecedent breast cancer. Br J Haematol. 2024;205(1):158\u201365. https:\/\/doi.org\/10.1111\/bjh.19432.","journal-title":"Br J Haematol"},{"issue":"11","key":"15366_CR40","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1038\/leu.2013.135","volume":"27","author":"C Meyer","year":"2013","unstructured":"Meyer C, Hofmann J, Burmeister T, Gr\u00f6ger D, Park TS, Emerenciano M, et al. The MLL recombinome of acute leukemias in 2013. Leukemia. 2013;27(11):2165\u201376. https:\/\/doi.org\/10.1038\/leu.2013.135.","journal-title":"Leukemia"},{"issue":"6","key":"15366_CR41","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.3324\/haematol.2015.137059","volume":"101","author":"S Salmoiraghi","year":"2016","unstructured":"Salmoiraghi S, Montalvo MLG, Ubiali G, Tosi M, Peruta B, Zanghi P, et al. Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival. Haematologica. 2016;101(6):e245\u20138. https:\/\/doi.org\/10.3324\/haematol.2015.137059.","journal-title":"Haematologica"},{"issue":"2","key":"15366_CR42","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1182\/blood-2014-02-558833","volume":"124","author":"A Stengel","year":"2014","unstructured":"Stengel A, Schnittger S, Weissmann S, Kuznia S, Kern W, Kohlmann A, et al. TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis. Blood. 2014;124(2):251\u20138. https:\/\/doi.org\/10.1182\/blood-2014-02-558833.","journal-title":"Blood"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15366-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15366-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15366-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T10:04:37Z","timestamp":1768385077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15366-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15366"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15366-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,29]]},"assertion":[{"value":"20 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}